[go: up one dir, main page]

AR131282A1 - NOVEL COMPOUNDS - Google Patents

NOVEL COMPOUNDS

Info

Publication number
AR131282A1
AR131282A1 ARP230103313A ARP230103313A AR131282A1 AR 131282 A1 AR131282 A1 AR 131282A1 AR P230103313 A ARP230103313 A AR P230103313A AR P230103313 A ARP230103313 A AR P230103313A AR 131282 A1 AR131282 A1 AR 131282A1
Authority
AR
Argentina
Prior art keywords
novel compounds
compounds
novel
methods
general formula
Prior art date
Application number
ARP230103313A
Other languages
Spanish (es)
Inventor
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina Mesch
Anglique Patiny-Adam
Christian Schnider
Jonathan Martin Shannon
Sandra Steiner
Andreas Michael Tosstorff
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR131282A1 publication Critical patent/AR131282A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general (1) en donde R¹, R², X y W son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.The invention relates to novel compounds having the general formula (1) wherein R¹, R², X and W are as described herein, a composition including the compounds and methods of using the compounds.

ARP230103313A 2022-12-08 2023-12-06 NOVEL COMPOUNDS AR131282A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22212126 2022-12-08

Publications (1)

Publication Number Publication Date
AR131282A1 true AR131282A1 (en) 2025-03-05

Family

ID=84462879

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230103313A AR131282A1 (en) 2022-12-08 2023-12-06 NOVEL COMPOUNDS

Country Status (6)

Country Link
EP (1) EP4630420A1 (en)
JP (1) JP2025540258A (en)
CN (1) CN120303272A (en)
AR (1) AR131282A1 (en)
TW (1) TW202440569A (en)
WO (1) WO2024121184A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN121358737A (en) * 2023-06-03 2026-01-16 成都赜灵生物医药科技有限公司 Pyridazines and uses thereof
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025180453A1 (en) * 2024-02-28 2025-09-04 纽欧申医药(上海)有限公司 Pyridazine ring derivative and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190793A1 (en) 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing
CN116867769A (en) * 2021-02-08 2023-10-10 南京明德新药研发有限公司 Substituted pyridazine phenol derivatives

Also Published As

Publication number Publication date
JP2025540258A (en) 2025-12-11
EP4630420A1 (en) 2025-10-15
CN120303272A (en) 2025-07-11
TW202440569A (en) 2024-10-16
WO2024121184A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
AR131282A1 (en) NOVEL COMPOUNDS
CL2023003312A1 (en) NLRP3 inhibitors
AR131006A1 (en) NOVEL COMPOUNDS
CL2022001091A1 (en) Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors (application divisional 202001871).
AR130984A1 (en) NOVEL COMPOUNDS
CL2021001330A1 (en) New heterocyclic compounds
CO2023014721A2 (en) Heterocyclic compounds
AR123424A1 (en) NEW HETEROCYCLIC COMPOUNDS
AR131278A1 (en) NOVEL COMPOUNDS
CO2023016212A2 (en) Triazine derivatives and their use in cancer treatment
CL2024004085A1 (en) Macrocyclic Kras inhibitor compounds, used to treat cancer.
AR132377A1 (en) NOVEL COMPOUNDS
CL2022000802A1 (en) Heterocyclic arylmethylene compounds as kv1.3 potassium shaker channel blockers
AR132456A1 (en) NOVEL COMPOUNDS
CO2022002000A2 (en) New heterocyclic inhibitors of monoacylglycerol lipase (MAGL)
CL2023002429A1 (en) Novel pyrimidin-2-yl sulfonamide derivatives
CL2022000019A1 (en) New heterocyclic compounds
CO2025003256A2 (en) Novel deuterated derivatives of pyrimidin-2-yl sulfonamide
ECSP23089582A (en) SPIROINDOLINONE COMPOUNDS AS KV1.3 POTASSIUM AGITATOR CHANNEL BLOCKERS
CR20240203A (en) NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS
CL2025000126A1 (en) Indole sulfonamide derivative compounds and their use in treating myelin loss.
CL2025000125A1 (en) Indole sulfonamide derivative compounds and their use in treating myelin loss.
AR133076A1 (en) NOVEL COMPOUNDS
AR133375A1 (en) NOVEL COMPOUNDS
AR131633A1 (en) NOVEL PYRIMIDINYL SULFONAMIDE DERIVATIVES